Sino Biopharmaceutical Limited (1177.HK) dividend yield, history and 2029 forecast
What is the Sino Biopharmaceutical Limited (1177.HK) dividend yield?
Sino Biopharmaceutical Limited (1177.HK) dividend
1.8 %dividend yield at the HK$5.60 close of November 6, 2026
RMB 0.08a share paid in 2025, our report
- Paid in 2025: RMB 0.08 a share, up from RMB 0.05 in 2021
- Our base-case forecast: RMB 0.10 by November 2027, RMB 0.12 by November 2029
New accounts get one company's ready report free. No card.
Executive summary + 8 chapters · 20,071 words · 158 sources
Is Sino Biopharmaceutical Limited a good dividend stock? Does its cash cover the dividend?
Our report makes no buy or sell call. It checks the dividend against free cash flow, the cash the business has left after paying for buildings and equipment.
Cash also had to serve subsidiary partners and shareholders. Some subsidiaries have outside owners, who receive their share before the remainder reaches Sino’s listed shareholders. Sino then used cash for dividends and buybacks, while retaining funds for acquisitions and investments. Investment purchases may include financial products used to hold money, so they should not all be mistaken for spending on drug laboratories.
- 202519.4 %
- 202434.7 %
Dividends as a share of free cash flow (our arithmetic on the report's figures). Past the dashed line, the dividend cost more than the cash.
How much would Sino Biopharmaceutical Limited's dividend pay you?
HK$10,000 invested in Sino Biopharmaceutical Limited at its 1.8% dividend yield (our report of November 6, 2026) pays HK$180.00 in the first year, before tax. If its dividend per share keeps changing 12.5% a year, as it did from 2021 to 2025, and the dividends are reinvested, year 10 pays HK$676.82, with HK$3,736.39 received in all.
Before tax. Past dividend growth is not a promise. Information only, not investment advice.
Sino Biopharmaceutical Limited dividend forecast: how much will it pay by 2029?
Management historically gave no quarterly or annual financial guidance. Its current targets include a 50% share of 2026 revenue from innovative drugs and out-licensing, with gross margin of 80%. It also targets 27 innovative products in 2026 and 30 launches by 2027. Seven siRNA candidates are expected to submit applications to begin human testing between the second half of 2026 and the first half of 2027. The company met its 2025 innovative-product target, reporting 47.8% against 45%.
What is Sino Biopharmaceutical Limited's dividend yield at the report's price?
At HK$5.60 a share on 6 November 2026, Sino Biopharmaceutical Limited asks investors to value both a profitable medicines business and a portfolio of investments. The real question is what future earnings, drug launches and licensing deals that price already assumes.
How much does Sino Biopharmaceutical Limited pay per share?
The base dividend is CNY0.10 per share in 2027 and CNY0.11 in 2028. It reaches CNY0.12 in 2029. The bear case cuts it to CNY0.07 and then CNY0.05, while the bull case reaches CNY0.12, CNY0.14 and CNY0.15. Cash generation supports the base case, but research, acquisitions and payments to minority owners compete with dividends.
Results · RMB millions; per share in RMB; dividends per share in HK$ · 2025
- Revenue31,834.488
- Net income2,343.348
- EPS, diluted0.13
- Dividend per share (HK$)0.10
Questions about the Sino Biopharmaceutical Limited (1177.HK) dividend
Does Sino Biopharmaceutical Limited pay a dividend?
Yes. It paid RMB 0.08 a share in 2025.
What is the dividend on HK$100 of Sino Biopharmaceutical Limited shares?
About HK$1.80 a year at the 1.8 % dividend yield: HK$100 buys 18 shares at the November 6, 2026 close.
Is Sino Biopharmaceutical Limited's dividend covered by its cash?
Yes. Dividends took 19.4 % of free cash flow in 2025 and 34.7 % in 2024 (our arithmetic on the report's figures).
Where could Sino Biopharmaceutical Limited stock be by 2029?
Our report's forecast is HK$6.90 a share by November 2029, from the HK$5.60 close of November 6, 2026. Sino Biopharmaceutical Limited stock forecast →
More on Sino Biopharmaceutical Limited (1177.HK)
More Sino Biopharmaceutical Limited pages
Sino Biopharmaceutical Limited's own filings
This page shows the dividend. The report shows whether the cash pays for it.
The full report: an executive summary and 8 chapters, 20,071 words, 52 tables. Its first page opens here, no account needed.
How it is made: AI reads Sino Biopharmaceutical Limited's filings, writes the report, checks the numbers against them and cites each source, 158 in this one. How we work · Corrections
Read the full report freeNew accounts get one company's ready report free. No card.
Information only, not investment advice. A dividend can be cut; the forecast gives three cases with their chances. Prices are those of the date shown.